866-997-4948(US-Canada Toll Free)

Hypertrophic Cardiomyopathy Therapeutics Market - (By Drug Class: Beta Adrenergic Blocking Agents, Calcium Channel Blocker, Antiarrhythmic Agents, and Anticoagulants) - Global Industry Analysis, Pipeline Analysis, Size, Share, Growth, Trends, and Forecast, 2015 - 2023

Published By :

Transparency

Published Date : Nov 2015

Category :

Pharmaceutical

No. of Pages : 72 Pages

This report on the hypertrophic cardiomyopathy therapeutics market studies the current and future prospects of the global market. Hypertrophic cardiomyopathy occurs if heart muscle cells enlarge and cause the walls of the ventricles (usually the left ventricle) to thicken. However, the thickening may block blood flow out of the ventricle and the condition is called obstructive hypertrophic cardiomyopathy. Modern healthcare infrastructure, increasing sedentary lifestyle in young population and rising obese population are expected to propel the global hypertrophic cardiomyopathy therapeutics market.

The hypertrophic cardiomyopathy therapeutics market report comprises an elaborate executive summary, which includes a market snapshot that provides information about various segments and sub-segments of the market. It also provides information and data analysis of the global hypertrophic cardiomyopathy therapeutics market with respect to the segments based on the type of drug class, and their geographic analysis. A detailed qualitative analysis of driving and restraining factors for the market growth and future opportunities has been provided in the market overview section. This section of the report also provides market attractiveness analysis, and market share analysis by key players, thus presenting a thorough analysis of the overall competitive scenario in the global hypertrophic cardiomyopathy therapeutics market.

Table of Contents
 
1. Preface

1.1. Report Description
1.2. Market Segmentation
1.3. Research Methodology

2. Executive Summary
2.1. Hypertrophic Cardiomyopathy Therapeutics: Market Snapshot
2.2. Global Hypertrophic Cardiomyopathy Therapeutics Market Share, by Geography, 2014 & 2023 (Value %)
2.3. Global Hypertrophic Cardiomyopathy Therapeutics Market, by Drug Class, 2014 (US$ Mn)

3. Hypertrophic Cardiomyopathy Therapeutics Market - Industry Analysis
3.1. Introduction
3.2. Epidemiology and Prognosis: Hypertrophic Cardiomyopathy
3.3. Market Dynamics
3.3.1. Drivers
3.3.1.1. Driver 1: Increasing prevalence of chronic cardiovascular diseases to increase demand for effective treatments
3.3.1.2. Driver 2: High awareness associated with HCM in developed countries
3.3.2. Restraints
3.3.2.1. Restraint 1: Rising technological upgradation in devices such as defibrillators and pacemakers
3.3.3. Opportunities
3.3.3.1. Opportunity 1: Targeted therapy for hypertrophic cardiomyopathy
3.4. Market Attractiveness Analysis - Hypertrophic Cardiomyopathy Therapeutics Market, by Geography, 2014
3.5. Competitive Landscape 
3.6. Global Hypertrophic Cardiomyopathy Therapeutics Market Share, by Key Players, 2014 (%)

4. Market Segmentation – By Drug
4.1. Introduction
4.1.1. Global Hypertrophic Cardiomyopathy Therapeutics Market Revenue, by Drug Class, 2013–2023 (US$ Mn)
4.2. Global Beta Adrenergic Blocking Agents Market Revenue, 2013–2023 (US$ Mn) and Analysis
4.3. Global Calcium Channel Blockers Market Revenue, 2013–2023 (US$ Mn) and Analysis
4.4. Global Antiarrhythmic Agents Market Revenue, 2013–2023 (US$ Mn) and Analysis
4.5. Global Anticoagulants  Market Revenue, 2013–2023 (US$ Mn) and Analysis

5. Pipeline Analysis
5.1. Overview
5.2. Phase II and Phase I Clinical Trials

6. Market Segmentation – By Geography
6.1. Introduction
6.1.1. Global Hypertrophic Cardiomyopathy Therapeutics Market Revenue, by Region, 2013–2023 (US$ Mn)
6.2. North America Hypertrophic Cardiomyopathy Therapeutics Market Revenue, by Country, 2013–2023 (US$ Mn)
6.2.1. U.S. Hypertrophic Cardiomyopathy Therapeutics Market Revenue, 2013–2023, (US$ Mn)
6.2.2. Canada Hypertrophic Cardiomyopathy Therapeutics Market Revenue, 2013–2023, (US$ Mn)
6.3. Europe Hypertrophic Cardiomyopathy Therapeutics Market – Revenue, by Country, 2013–2023 (US$ Mn)
6.3.1. U.K. Hypertrophic Cardiomyopathy Therapeutics Market Revenue, 2013–2023, (US$ Mn)
6.3.2. Germany Hypertrophic Cardiomyopathy Therapeutics Market Revenue, 2013–2023, (US$ Mn)
6.3.3. Rest of Europe Hypertrophic Cardiomyopathy Therapeutics Market Revenue, 2013–2023, (US$ Mn)
6.4. Asia Pacific Hypertrophic Cardiomyopathy Therapeutics Market Revenue, by Country, 2013–2023 (US$ Mn)
6.4.1. India Hypertrophic Cardiomyopathy Therapeutics Market Revenue, 2013–2023, (US$ Mn)
6.4.2. Japan Hypertrophic Cardiomyopathy Therapeutics Market Revenue, 2013–2023, (US$ Mn)
6.4.3. Rest of APAC Hypertrophic Cardiomyopathy Therapeutics Market Revenue, 2013–2023, (US$ Mn)
6.5. Rest of the World Hypertrophic Cardiomyopathy Therapeutics Market Revenue, by Country, 2013–2023 (US$ Mn)
6.5.1. Latin America Hypertrophic Cardiomyopathy Therapeutics Market Revenue, 2013–2023, (US$ Mn)
6.5.2. Middle East Hypertrophic Cardiomyopathy Therapeutics Market Revenue, 2013–2023, (US$ Mn)
6.5.3. Africa Hypertrophic Cardiomyopathy Therapeutics Market Revenue, 2013–2023, (US$ Mn)

7. Recommendations
7.1. Recommendation 1: Companion diagnostics would help to increase the diagnostic rate and ultimately the drugs market 

8. Company Profiles
8.1. Astra Zeneca plc
8.2. Concordia Healthcare Corp.
8.3. Gilead Sciences, Inc.
8.4. Merck & Co., Inc.
8.5. Mylan N.V.
8.6. Novartis AG
8.7. Pfizer, Inc. 
8.8. Sanofi S.A.
8.9. Teva Pharmaceutical Industries Ltd

List of Table

NA

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *

Upcoming Reports